On November 27, 2024, Christian Nichols, Senior Vice President and Chief Commercial Officer at Alkermes, Inc., sold 5,208 shares of Alkermes PLC (ALKS, Financial). Following this transaction, the insider now owns 60,703 shares of the company. The details of this transaction can be found in the SEC Filing.
Alkermes PLC is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to research, develop, and commercialize pharmaceutical products. The company focuses on central nervous system disorders such as schizophrenia, depression, addiction, and multiple sclerosis.
Over the past year, Christian Nichols has sold a total of 15,625 shares and has not purchased any shares. The insider transaction history for Alkermes PLC indicates that there have been no insider buys and six insider sells over the same period.
On the day of the recent sale, shares of Alkermes PLC were trading at $29.15, giving the stock a market cap of $4.744 billion. The company's price-earnings ratio is 15.04, which is lower than the industry median of 22.78 and also lower than the company’s historical median price-earnings ratio.
With a price of $29.15 and a GF Value of $28.58, Alkermes PLC has a price-to-GF-Value ratio of 1.02, indicating that the stock is fairly valued based on its GF Value. The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company’s past returns and growth, and future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
